Mammary Cell News Volume 4.13 | Apr 5 2012

LABORATORY RESEARCH

SIX1 Induces Lymphangiogenesis and Metastasis via Upregulation of VEGF-C in Mouse Models of Breast Cancer
Scientists defined a critical role for SIX1 in lymphatic dissemination of breast cancer cells, providing a direct mechanistic explanation for how VEGF-C expression is upregulated in breast cancer, resulting in lymphangiogenesis and metastasis. [J Clin Invest] Abstract | Press Release

Estrogen Promotes ER-Negative Tumor Growth and Angiogenesis through Mobilization of Bone Marrow-Derived Monocytes
Researchers showed how estrogen can promote the outgrowth of murine xenograft tumors established from patient-derived estrogen receptor (ER)-negative breast cancer cells by influencing the mobilization and recruitment of a pro-angiogenic population of bone marrow-derived myeloid cells. [Cancer Res] Abstract

Receptor Activator of NF-KappaB Ligand Promotes Proliferation of a Putative Mammary Stem Cell Unique to the Lactating Epithelium
Researchers showed that CD49f⁺ primary mammary epithelial cells isolated from lactating tissue uniquely respond to pregnancy-associated hormones compared to CD49f⁺ cells from non-lactating tissue. [Stem Cells] Abstract

Delivery of Chemo-Sensitizing siRNAs to HER2⁺-Breast Cancer Cells Using RNA Aptamers
Scientists describe a novel cell-based selection methodology that enables the identification of cell-internalizing RNA aptamers for targeting therapeutic small interfering RNAs (siRNAs) to human epidermal growth factor receptor 2 (HER2)-expressing breast cancer cells. [Nucleic Acids Res] Abstract

Mammary Tumor Growth and Pulmonary Metastasis Are Enhanced in a Hyperlipidemic Mouse Model
Researchers suggest that the hypercholesterolemic milieu in apolipoprotein E knockout mice is a favorable setting for mammary tumor growth and metastasis. [Oncogene] Abstract

CD133⁺ Cells with Cancer Stem Cell Characteristics Associates with Vasculogenic Mimicry in Triple-Negative Breast Cancer
Researchers suggest that a subpopulation of cells with holoclone morphology, CD133⁺ phenotype and cancer stem cell characteristics may have the capacity of transdifferentiation and contribute to vasculogenic mimicry in triple-negative breast cancer. [Oncogene] Abstract

Mechanisms of Estrogen-Independent Breast Cancer Growth Driven by Low Estrogen Concentrations Are Unique versus Complete Estrogen Deprivation
Researchers hypothesized that a subset of patients receiving aromatase inhibitor therapy maintain low circulating concentrations of estrogens that influence the development of endocrine resistance. [Breast Cancer Res Treat] Abstract

Small Molecule Antagonists of the Wnt/Beta-Catenin Signaling Pathway Target Breast Tumor-Initiating Cells in a Her2/Neu Mouse Model of Breast Cancer
To identify signaling pathways that might be targeted to eliminate breast tumor-initiating cells (BTIC), while sparing their normal stem and progenitor cell counterparts, researchers performed global gene expression profiling of BTIC- and mammary epithelial stem/progenitor cell enriched cultures derived from mouse mammary tumors and mammary glands. [PLoS One] Abstract

CLINICAL RESEARCH

Correlation of Treatment-Emergent Adverse Events and Clinical Response to Endocrine Therapy in Early Breast Cancer: A Retrospective Analysis of the German Cohort of TEAM
A retrospective analysis of the German cohort of the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial was carried out to assess disease-free survival and overall survival in patients with and without arthralgia/myalgia and/or menopausal symptoms during adjuvant endocrine treatment. [Ann Oncol] Abstract

Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-Positive Locally Recurrent or Metastatic Breast Cancer
Researchers report the first results from a phase II, open-label study designed to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab and capecitabine as first-line therapy for human epidermal growth factor receptor (HER)-2-positive locally recurrent or metastatic breast cancer. [Oncologist] Abstract

Peptide Vaccine Stimulates Immune Response in Patients with Breast Cancer
According to 24-month results, patients with breast cancer assigned to the HER2-based peptide vaccine AE37 had immunologic responses compared with a control group. [Press release from the American Association for Cancer Research (AACR) discussing research presented at the AACR Annual Meeting 2012, Chicago] Press Release

Older Patients with Certain Breast Cancer Subtype May Not Benefit from Radiation Therapy
New research suggests local breast radiation therapy may not be necessary for women with the luminal A subtype of breast cancer, particularly those aged older than 60. [Press release from the American Association for Cancer Research (AACR) discussing research presented at the AACR Annual Meeting 2012, Chicago] Press Release

Long-Term Use of Estrogen Hormone Therapy Linked to Higher Risk for Breast Cancer
Researchers have linked the long-term use of estrogen plus progesterone and estrogen-only hormone therapy with a higher risk for developing breast cancer. [Press release from the American Association for Cancer Research (AACR) discussing research presented at the AACR Annual Meeting 2012, Chicago]
Press Release

Link Between Inflammation and Breast Cancer Metastases Identified, May Be Treatable
The incidence of breast cancer-associated metastasis was increased in animal models of the chronic inflammatory condition arthritis, according to preclinical results. [Press release from the American Association for Cancer Research (AACR) discussing research presented at the AACR Annual Meeting 2012, Chicago] Press Release

Canada and Japan Establish New Research Partnership
The Canadian Institutes of Health Research and the Japan Science and Technology Agency recently signed a partnership agreement to fund joint research projects on the epigenetics of stem cells. [Canadian Institutes of Health Research] Press Release

CRT and the EIF Unveil Innovative £50 Million Cancer Fund to Bridge Development Gap in the UK
Cancer Research Technology, (CRT) and the European Investment Fund (EIF) have joined together to create a £50 million investment fund to bridge the funding gap in the UK between cancer drug discovery and early development. [Cancer Research UK] Press Release

Mechanisms of Alcohol-Associated Cancers (R01) (PA-12-146) [National Institutes of Health, United States]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 10^th International Congress on Targeted Anticancer Therapies (TAT) 2012
September 24-26, 2012
Amsterdam, The Netherlands

Visit our events page to see a complete list of events in the mammary cell community.

Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Hematology (STEMCELL Technologies, Inc.)

Scientist – hPSC (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Postdoctoral Fellow and Technician Positions (North Carolina Central University)

Postdoctoral Position – Breast Cancer/Stem Cell Biology (University of Cincinnati – College of Medicine)

Postdoctoral Research Fellow (Cancer Research UK – Cambridge Research Institute) 

Post-Doctoral Position – Translational Breast Cancer Research (ISREC/EPFL)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Middle East to Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.